Author

Samantha Rokey

University of Arizona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2

Frequent Co-Authors

Christopher HulmeiD· 2 shared Gerrit WilmsiD· 2 shared Sean Brendan Ginn· 2 shared Walter B. BeckeriD· 2 shared A. Philip McMahon· 1 shared Aditi Mandar Atmasidha· 1 shared Aidan McMahon· 1 shared Alan R. PrescottiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Christopher HulmeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation

Samantha K. Bartholomew, Julie Turk, Wendy Winslow, Christopher Foley, Arthur Y. Shaw, Samantha Rokey, Savannah Tallino, Jessica M. Judd, Thomas G. Beach, Geidy E. Serrano, Gerrit Wilms, Ragini Kushwaha, Aidan McMahon, Sean Brendan Ginn, Walter B. Becker, , Ramón Velázquez

This study shows that inhibiting Dyrk1a with the compound DYR533 reduces tau pathology, neuroinflammation, and amyloidosis in mouse models of neurodegenerative diseases.

bioRxiv · Jan 23, 2026 · PreprintNeuroscience

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalling

Vasudha Tandon, Alessandra Fistrovich, Joaquina Nogales, Febe Ferro, Samantha Rokey, Carly R. Cabel, Amy Dunne Miller, Mary Yagel, Christina Duncan, Aditi Mandar Atmasidha, Ira Sharma, Gerrit Wilms, Karin Williams, Richard J. R. Elliott, Timothy Chavez, , Sourav Banerjee

This paper designs and evaluates Dyr726, a brain-penetrant multi-kinase inhibitor that targets PI3Kα, receptor tyrosine kinases, and WNT signaling, showing efficacy in preclinical cancer models.

bioRxiv · Mar 26, 2025 · PreprintCancer Biology